Macquarie Group’s Maravai LifeSciences MRVI Stock Holding History

Macquarie Group’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-221,651	Closed	-$1.84M	–	1699
2024 Q3	$1.84M	Sell	221,651 -228,420	-51%	-$1.97M	﹤0.01%	1252
2024 Q2	$3.22M	Buy	450,071 +171,009	+61%	+$1.48M	﹤0.01%	1088
2024 Q1	$2.42M	Buy	+279,062	New	+$1.89M	﹤0.01%	1166
2023 Q2	–	Sell	-101,896	Closed	-$1.43M	–	1709
2023 Q1	$1.43M	Hold	101,896	–	–	﹤0.01%	1271
2022 Q4	$1.46M	Sell	101,896 -64,411	-39%	-$1.01M	﹤0.01%	1303
2022 Q3	$4.27M	Buy	166,307 +16,219	+11%	+$407K	0.01%	1030
2022 Q2	$4.26M	Buy	150,088 +22,075	+17%	+$699K	﹤0.01%	1072
2022 Q1	$4.51K	Sell	128,013 -81,735	-39%	-$2.74M	﹤0.01%	1141
2021 Q4	$8.79M	Buy	209,748 +61,478	+41%	+$2.49M	0.01%	970
2021 Q3	$7.28M	Sell	148,270 -117,518	-44%	-$5.73M	0.01%	1004
2021 Q2	$11.1M	Buy	+265,788	New	+$10.3M	0.01%	912

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Macquarie Group's MRVI Position: Q4 2024 in Review

Macquarie Group sold out of Maravai LifeSciences (MRVI) in Q4 2024, closing a stake of 221,651 shares — an estimated $1.84M sold.

Macquarie Group first reported a position in MRVI in Q2 2021 and held it in 11 quarters. The position peaked at $11.1M in Q2 2021. 185 funds tracked by Wall St. Rank hold MRVI as of Q4 2024.

Macquarie Group reported no remaining Maravai LifeSciences position as of Q4 2024 after selling out during the quarter.
Macquarie Group sold 221,651 Maravai LifeSciences shares in Q4 2024, an estimated $1.84M.
Macquarie Group first reported a position in Maravai LifeSciences in Q2 2021 and held it in 11 quarters.
Macquarie Group's Maravai LifeSciences position peaked at $11.1M in Q2 2021.
185 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q4 2024.

Based on Macquarie Group's 13F filing for Q4 2024, filed 14 Feb 2025.